CLINICO-THERAPEUTIC STUDIES ON CANINE TRANSMISSIBLE VENEREAL TUMOUR

M. Athar, A. Suhail, G. Muhammad, A. Shakoor and F. Azim
Faculty of Veterinary Science, University of Agriculture, Faisalabad 38040, Pakistan

ABSTRACT

Ten-bitches and 8-male dogs afflicted with transmissible venereal tumour (TVT) randomly divided into 3 groups viz. Group-I, Group-II and Group-III comprising 6 dogs each, were subjected to three different protocols. Group-I was treated surgically. A complete regression of the tumour mass was observed in 4 (66.67%) dogs, while 2 (33.34%) had incomplete regression at the end of first 5 weeks. A 16.67% recurrence rate was also observed at the end of 6 months study period. In Group-II, chemotherapy with intravenous injection of vincristine sulphate @ 0.025 mg/kg b.wt. affected 80.33% (n=5) complete regression whereas incomplete regression was recorded in only one (16.67%) subject at the end of 5th week. Vomiting and inappetance as side-effects were also noticed. Group-III was subjected to a combination of surgery and chemotherapy where vincristine sulphate was used after surgical debulking of tumour mass. A 100% regression even after 2–3 injections with no recurrence was achieved till 6 months post-treatment. There was a significant increase (P<0.01) in erythrocyte sedimentation rate and total leukocyte count (TLC) in TVT-affected dogs which returned to normal after 2–5 weeks of treatment. Vincristine sulphate had a significant decreasing effect on TLC in both Group-II and Group-III, which was transient.

Key words: Transmissible venereal tumour; Vincristine; Oncology; Cancer therapy.

INTRODUCTION

Among the commonly encountered afflictions of dogs, transmissible venereal tumour (TVT) is a naturally occurring, coitally-transmitted neoplastic disorder that affects the external genitalia of both sexes, vulva and vagina in females; penis and prepuce in male dogs (Vermooten, 1987). Metastasis to other tissues (skin, nasal passage, oral cavity, etc.) has been seen in about 5–6.9 percent of the cases (Oduye et al., 1973; Das et al., 1990). A recent report from Portugal has indicated brain and ocular metastases in a dog afflicted with TVT (Ferreira et al., 2000) Although, this tumour can be treated surgically, frequent recurrence following surgery (Catinelli et al., 1978) due to the growth of the residual tumour warrants the use of some alternative method which could be curative even when the tumour has infiltrated to adjacent tissues or metastasized to other organs. Furthermore, surgery is a difficult preposition in field situations where facilities even for minor surgical manipulations are lacking. Chemotherapy with anticancer drugs like vincristine sulphate holds the promise of a suitable alternative to surgery (Brown et al., 1980; Singh et al., 1996). Present study was thus planned to evaluate the comparative recovery rates of surgery and vincristine sulphate, alone and in combination in the therapy of TVT.

MATERIALS AND METHODS

Patients and Diagnosis of TVT

Eighteen dogs (10 females and 8 males) brought to the outdoor clinics of the Department of Veterinary Clinical Medicine and Surgery, University of Agriculture, Faisalabad with a history of serosanguineous discharge and presence of granulomatous (tumorous) lesion(s) in and around their genitalia were selected and included in this study. The diagnosis of the condition rested on pathognomonic signs and histopathology (Sandritter & Wartman, 1969). To this end, 1 × 1 cm² biopsy specimens from granulomatous lesions were collected from each dog under study and preserved in 10 per cent neutral buffered formalin. Each specimen was then processed for histopathologic examination to see any change both at tissue (×100) and cellular levels (×400).

Treatment Protocols

The patients were divided randomly into three groups viz. Group-I, Group-II and Group-III, each comprising 6 subjects. The dogs in Group-I were treated surgically by debulking (removal) of the tumorous mass (Bojjab, 1997). Dogs in Group-II were treated with a chemotherapeutic agent viz. vincristine sulphate, whereas dogs in Group-III were subjected to a combination protocol of surgery and chemotherapy.
Vincristine sulphate was used after the surgical debulking of the tumourous mass. In the later two groups, vincristine sulphate (Oncovin - Lilly, France) was used as 0.01% solution @ 0.025 mg/kg b.wt. by slow intravenous injection (Ganesh et al., 1993; Barragry, 1994). Vincristine sulphate therapy was repeated at weekly intervals for 5 consecutive weeks.

**Haematologic Examination**

Blood samples from all subjects were collected for complete haematologic examination including total erythrocyte (TEC) and leucocyte (TLC) counts, haemoglobin concentration (Hb), packed cell volume (PCV), and erythrocyte sedimentation rate (ESR) both in pre-treatment and post-treatment time points (Benjamin, 1978). Pre-treatment values were compared with those of post-treatment values recorded at day 15, 29, and day 43.

**Response to the treatment**

Response of a treatment protocol was evaluated on the basis of the regression of tumour size, effect on various haematologic parameters (TEC, TLC, PCV, Hb, ESR), and recurrence during first 6 months post-treatment. The data, thus collected, were subjected to statistical analysis (Steel and Torrie, 1980). Side-effects and any untoward sequelae of surgery and/or chemotherapy, if any, were also recorded. A final examination of the subjects was conducted 6 months after the treatments for evaluating the recurrence rate.

**RESULTS**

**Pre-treatment clinical findings**

Transmissible venereal tumours (TVT) were rounded to diffused swellings and appeared to be lobulated, cauliflower-like red to grayish-pink mass. In females (n=10), the tumour was located in the vestibule (n=1; 10%), in both vulva and vagina (n=5; 50%) and in the vagina (n=4; 40%) (Plate 1). Whereas in males (n=8), tumours were located on the posterior portion of the penis (n=4; 50%) on the preputial mucosa (n=1; 12.5%) and in both prepuce and penis (n=3; 37.5%) (Plate 2). Metastasis to the regional (inguinal) lymph nodes was recorded in only one (5.56%) subject whereas two subjects (11.12%) were found to have metastasis in the nasal chamber. Bleeding and sneezing was evident from nostrils in these two dogs. On histopathological examination, haematoxylin-eosin stained biopsy samples revealed sheets of cells appearing uniformly in size, fibrous stroma distributed unevenly, plenty of newly formed blood vessels, and pleomorphic nuclei (Plate 3). At high magnification, prominent nuclei, frequent mitotic figures and cellular infiltration mainly of lymphocytes were also seen (Plate 4).

Plate 1. Transmissible venereal tumour in a female dog. A cauliflower-like granulomatous mass protruding out of the vulva.

Plate 2. Transmissible venereal tumour in male dog. Note the involvement of shaft of penis and prepuce.

**Treatment response**

In Group-I, complete surgical excision of tumour mass could be performed in 4 (66.67%) of 6 subjects, whereas in the remaining two subjects, extensive involvement of the surrounding tissues and inaccessible sites made complete surgical excision not achievable. When re-examined 6 months later, 5 had complete regression while recurrence was observed in one (16.67%) subject only (Table 1).

Of the six subjects treated with vincristine sulphate (Group-II), 5 had complete regression of the lesion following 3–5 injections at weekly intervals (Table 1). Majority of dogs (n=3) recovered completely with 4 injections whereas in one dog, complete recovery was
achieved after 3 and in the 5th dog after completing 5 injections. In the remaining one case, although the regression was incomplete, but a significant regression (P ≤ 0.05) in the tumour size was observed after the completion of 5 injections course. In none of the dogs vincristine was administered beyond 5th week. No recurrence was observed in any of the dog till 6 months post-vincristine sulphate therapy. Vomiting and inappetance were recorded in one dog each during first 48 hours.

Haematological values

No significant change in the TEC from normal as well as difference among groups was observed when haematologic examination carried out before the initiation of any treatment protocol. A significant (P≤0.05) rise in TLC was noticed in all 3 groups before the initiation of any treatment protocol (Table 2). When observed during the post-therapy period of 6 weeks, a significant fall (P≤0.05) in TLC was recorded in all three groups, especially in Groups-II and III where it reduced to 6.97 ± 5.12 and 6.78 ± 1.26 thousands per microlitre, respectively (P≤0.01). No significant change from normal and difference among all three groups was observed in PCV before and after the initiation of treatment. A similar non-significant change from normal and difference among all three groups was observed in haemoglobin concentration before and after the initiation of treatment. A significant rise (P≤0.01) in ESR values ranging from 38.00 ± 9.30 to 42.20 ± 18.00 was observed in all three groups when proceeded before treatment. After two weeks of the initiation of therapy, a significant (P≤0.05) fall in ESR values was observed in all three groups which did not differ significantly amongst them (Table 2). At the end of 6 weeks period, all the groups had a significantly low, almost normal (P≤0.01) ESR values which differed non-significantly amongst the groups.

DISCUSSION

In the present study, the lesions of transmissible venereal tumours (TVT) in male dogs were confined to penis and prepuce whereas in bitches, vagina, vestibule, and vulva were commonly involved sites. These findings are in line with those of Bernardori et al. (1973), Spence et al. (1978), and Gordon and Bruce (1979). Metastasis occasionally occurs to the inguinal lymph nodes, skin, spleen, liver, and lungs, and appears to be mainly by lymphatic pathway or by oral implantation (McLeod and Lewis, 1972; Oduye et al., 1973; Das et al., 1991; Ayyappan et al., 1994). Das et al. (1991) reported a metastasis of 6.9% developed elsewhere in the body. In the present study, metastasis could be detected in 2 (11.12%) of the 18 subjects which is lower than that of Das et al. (1991).
Table 1: Comparison of different treatment protocols of TVT in dogs

<table>
<thead>
<tr>
<th>Group</th>
<th>No. of Dogs</th>
<th>No. of dogs</th>
<th>Complete Regression in tumour mass at 5 weeks</th>
<th>Incomplete Recurrence after 6 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>6</td>
<td>4</td>
<td>66.67%</td>
<td>2</td>
</tr>
<tr>
<td>II</td>
<td>6</td>
<td>5</td>
<td>80.33%</td>
<td>1</td>
</tr>
<tr>
<td>III</td>
<td>6</td>
<td>6</td>
<td>100.00%</td>
<td>0</td>
</tr>
</tbody>
</table>

Group-I = Surgery only  Group-II = Vincristine sulphate  Group-III = Surgery + vincristine sulphate

| Group-III | 1 | 16.67\% |

Table 2: Effect of surgery and vincristine sulphate alone and in combination on total leukocyte counts and erythrocyte sedimentation rates

<table>
<thead>
<tr>
<th>Weeks</th>
<th>Group-I</th>
<th>Group-II</th>
<th>Group-III</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 (Pre-treatment)</td>
<td>10.06 ± 3.11</td>
<td>10.81 ± 3.21</td>
<td>9.97 ± 2.60</td>
</tr>
<tr>
<td>2 (Post-treatment)</td>
<td>9.65 ± 2.11</td>
<td>6.55 ± 5.34</td>
<td>6.89 ± 3.42</td>
</tr>
<tr>
<td>4 (Post-treatment)</td>
<td>8.50 ± 1.51</td>
<td>6.89 ± 4.62</td>
<td>6.54 ± 1.92</td>
</tr>
<tr>
<td>6 (Post-treatment)</td>
<td>8.10 ± 0.98</td>
<td>6.97 ± 5.12</td>
<td>6.78 ± 1.26</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Weeks</th>
<th>Group-I</th>
<th>Group-II</th>
<th>Group-III</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 (Pre-treatment)</td>
<td>42.20 ± 18.00</td>
<td>47.80 ± 13.50</td>
<td>38.00 ± 9.30</td>
</tr>
<tr>
<td>2 (Post-treatment)</td>
<td>20.10 ± 11.00</td>
<td>13.00 ± 8.90</td>
<td>15.00 ± 4.30</td>
</tr>
<tr>
<td>4 (Post-treatment)</td>
<td>2.80 ± 1.70</td>
<td>2.70 ± 3.60</td>
<td>4.70 ± 2.90</td>
</tr>
<tr>
<td>6 (Post-treatment)</td>
<td>2.40 ± 1.10</td>
<td>2.20 ± 2.70</td>
<td>3.60 ± 2.10</td>
</tr>
</tbody>
</table>

Group-I = Surgery only  Group-II = Vincristine sulphate  Group-III = Surgery + vincristine sulphate

On histopathologic examination, cells were found present in the form of uniform sheets with prominent pleomorphic nuclei and mitotic activities. Cytoplasmic vacuolation and fibrous stroma was distributed unevenly. These findings which formed the basis of confirmatory diagnosis of TVT in the present study are congruous with the description given by previous workers (Hill et al., 1984; Morgan, 1992; Dinesh et al., 1993; Ayyapan et al., 1994).

Although surgery is the most widely used method in the treatment of TVT, inaccessibility of the site, incomplete excision, and metastasis may explain the recurrence of the TVT following surgery (Catinelli et al., 1978). In the present study, of the six dogs treated surgically (Group-I), the tumour mass could not be completely excised in two bitches where the lesion was inaccessible due to its spread to the surrounding tissues as well as the cervix. Even complete episiotomy incision could not help. Of these two cases, at the end of 6 months study period, one had completely regressed lesion whereas the other had the regenerates. This post-operative self-regression may be due to the provocation of the body’s own immune system with the release of tumour cells in the circulation and ensuing lymphoblastogenesis as well as humoral response. The recurrence could be due to a weak lymphoblastogenic response (Morgan, 1992).

Owing to the minor side-effects, vincristine sulphate, an alkaloid isolated from *Vinca rosa*, has also been widely used anticancerous drug in veterinary practice. It is an antimitotic agent which prevents mitosis by abolishing spindle formation (Barragry, 1994). When using vincristine sulphate @ 0.025 mg/kg b.wt, in the dogs of Group-II, complete regression was observed in 5 (80.33\%) of six dogs and in one dog (16.67\%) incomplete but significant regression was observed after the completion of 5 injections course. Majority of dogs (n=3) recovered completely with 4 injections where as in the remaining two cases, complete recovery was achieved after 3 and 5 injections, respectively. No recurrence was observed in any of dog treated with vincristine sulphate till 6 months post-treatment. Vomiting and inappetence was observed in one dog each during first 48 hours. In the combination protocol (Group-III) where injections of vincristine sulphate were used following surgical excision of tumour mass, 100% regression was observed. In none of the dogs of this group, vincristine was used for more than 3 times. This would not only lead to a hastened recovery in the affected dogs but also would try to minimize the potential risks involved in the anticancer drug therapy i.e., severe leukopenia, thrombocytopenia, etc. to name a few (Barragry, 1994). No such report regarding the combination mode of therapy could be found from the available literature.

The increase in ESR and TLC is due to some inflammatory or pathological process going on in the body (Benjamin, 1978). Vincristine sulphate has a significant decreasing effect on TLC which is usually transient (Ganesh et al., 1993). This is also consistent...
REFERENCES


